Universitätsklinikum Essen, Klinik für Hämatologie
Essen, Germany
Hospital department in Essen, North Rhine-Westphalia
Hufelandstraße 55, 45147 Essen
About Universitätsklinikum Essen, Klinik für Hämatologie
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
3
University of Heidelberg Medical Center
2
Celgene Corporation
1
Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH
1
International Extranodal Lymphoma Study Group (IELSG)
1
Pharmacyclics LLC.
1
Prof. Dr. M. Dreyling (co-chairman)
1
University Hospital Muenster
1
University Hospital, Essen
1
University of Cologne
1
University of Jena
1
Clinical Trials at Universitätsklinikum Essen, Klinik für Hämatologie
During the past decade, Universitätsklinikum Essen, Klinik für Hämatologie conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 1 clinical trials were completed, i.e. on
average, 12.5% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes
2003-06-01
2007-02-01
Completed
215
Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
2009-07-01
2012-12-01
Completed
214
Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
2009-11-01
2017-03-01
Completed
126
Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL
2009-05-09
2018-12-01
Unknown status
128
TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study
2012-08-24
2022-05-31
Completed
717
Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas
2013-01-01
2020-02-20
Completed
37
Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy
2015-02-03
2022-07-13
Completed
60
An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical Practice
2014-07-08
2019-07-22
Completed
688
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Universitätsklinikum Essen, Klinik für Hämatologie" #1 sponsor was "Hoffmann-La Roche" with 3 trials, followed by "University of Heidelberg Medical Center" with 2 trials
sponsored, "Celgene Corporation" with 1 trials sponsored, "Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH" with 1 trials sponsored and "International Extranodal Lymphoma Study Group (IELSG)"
with 1 trials sponsored. Other sponsors include 3 different institutions and
companies that sponsored additional 13 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsklinikum Essen, Klinik für Hämatologie"
#1 collaborator was "AbbVie" with 1 trials as a collaborator, "Amgen" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Celgene" with 1 trials as a collaborator and "Celgene Corporation" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were
collaborators in the rest 14 trials.
Clinical Trials Conditions at Universitätsklinikum Essen, Klinik für Hämatologie
According to Clinical.Site data, the most researched conditions in "Universitätsklinikum Essen, Klinik für Hämatologie" are
"Multiple Myeloma" (2 trials), "Myelodysplastic Syndromes" (2 trials), "Acute Myeloid Leukemia" (1 trials), "Acute Myeloid Leukemia in Remission" (1 trials) and "B-cell Lymphoma" (1 trials). Many other conditions were trialed in "Universitätsklinikum Essen, Klinik für Hämatologie" in a lesser frequency.
Clinical Trials Intervention Types at Universitätsklinikum Essen, Klinik für Hämatologie
Most popular intervention types in "Universitätsklinikum Essen, Klinik für Hämatologie" are "Drug" (15 trials), "Device" (1 trials), "Other" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.
The name of intervention was led by "Bortezomib" (3 trials), "Dexamethasone" (3 trials), "Lenalidomide" (3 trials), "Rituximab" (3 trials) and "Venetoclax" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Universitätsklinikum Essen, Klinik für Hämatologie
The vast majority of trials in "Universitätsklinikum Essen, Klinik für Hämatologie" are
16 trials for "All" genders.
Clinical Trials Status at Universitätsklinikum Essen, Klinik für Hämatologie
Currently, there are NaN active trials in "Universitätsklinikum Essen, Klinik für Hämatologie".
undefined are not yet recruiting,
1 are recruiting,
5 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 9 completed trials in Universitätsklinikum Essen, Klinik für Hämatologie,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Universitätsklinikum Essen, Klinik für Hämatologie, 2 "Phase 1"
clinical trials were conducted, 9 "Phase 2" clinical
trials and 7 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".